Drugs Made In America Acquisition II Corp. (DMII)

Drugs Made In America Acquisition II Corp. is a special purpose acquisition company, or blank-check company, formed in 2024 to complete a merger, share exchange, asset acquisition or similar business combination with one or more operating businesses. It is based in New York City and is a sister vehicle to Drugs Made In America Acquisition Corp.

The company intends to focus its search on targets in the pharmaceutical sector, consistent with its name's emphasis on drug production in the United States.

It completed its initial public offering on Nasdaq in September 2025, selling units at ten dollars each, and its ordinary shares trade under the ticker DMII. Offering proceeds are held in a trust account until a business combination is completed or the funds are returned to shareholders.